2020 ACTT-2 TRIAL Baricitinib plus Remdesivir for Hospitalized Adults with Covid-1 Double-blind, randomized, placebo-controlled trial M Objective: To compare the clinical efficacy of combination of baricitinib plus remdesivir with remdesivir alone among hospitalized adults with laboratory-confirmed Covid-19. 1033 patients Patients with lab-confirmed SARS-CoV-2 infection with illness of any duration and atleast one of the following: […]
Tag: covid 19
ACTT-1 Trial Summary: Remdesivir in Covid-19
2020 ACTT-1 TRIAL Remdesivir for the Treatment of Covid-19 Double-blind, randomized, placebo-controlled trial Objective: To evaluate the clinical efficacy and safety of putative investigational therapeutic agent remdesivir among hospitalized adults with laboratory-confirmed Covid-19. M Patients with lab-confirmed SARS-CoV-2 infection 1,063 with illness of any duration and atleast one of the patients following: radiographic infiltrates OR […]
ACTT-4 Trial Summary: Baricitinib in Covid-19
2022 ACTT-4 TRIAL Baricitinib versus dexamethasone for adults hospitalised with COVID-19 double-blind, double placebo-controlled, randomised controlled trial M Objective: To compare baricitinib in combination with remdesivir versus dexamethasone with remdesivir at preventing progression to mechanical ventilation or death 1010 patients Inclusion criteria: Adults ≥18 years with COVID-19 who required supplemental oxygen administered by low-flow ($15 […]
ACTIV-4B Trial Summary: Antithrombotic Therapy in Covid-19
2021 ACTIV-4B TRIAL Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19 minimal-contact, adaptive, randomized, double-blind, placebo-controlled Objective: To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable outpatients with COVID-19. 657 patients Inclusion criteria: Participants 40 to 80 years of […]
ACTIV-3 Trial: Monoclonal Antibody for Covid-19
2020 ACTIV-3 TRIAL Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 Multicenter, open-label, randomized comparative trial M Objective: To assess the efficacy of LY-CoV555, a neutralizing monoclonal antibody in hospitalized Covid-19 patients without end-organ damage. Hospitalized patients with Covid-19 who had symptoms 314 for ≤12 days. Excluded from the trial were patients who patients had […]
ACTION Trial Summary: Anticoagulation for Hospitalized Covid-19 Patients
2021 ACTION TRIAL: Therapeutic vs. prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer Pragmatic, open-label (with blinded adjudication), multicentre, randomised Objective: to evaluate therapeutic anticoagulation compared with prophylactic anticoagulation among patients admitted with coronavirus disease 2019 (COVID-19) infection. 615 patients Inclusion Criteria: Patients (aged ≥18 years) hospitalised with COVID-19 and elevated […]
MICHELLE Trial Summary: Rivaroxaban for Thromboprophylaxis in Covid-19
2022 MICHELLE TRIAL Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 Pragmatic, open-label, multicentre, randomized controlled trial Objective: To investigate if extended thromboprophylaxis with Rivaroxaban after hospitalization due to COVID-19 decrease rates of venous & arterial thromboembolism in high-risk patients 320 patients Patients ≥ 18 years hospitalized for ≥3 days with COVID-19 […]